Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Shanghai Junshi Bioscience Co., Ltd.
DEKA Biosciences
ImmunityBio, Inc.
ImmunityBio, Inc.
Immodulon Therapeutics Ltd
Eli Lilly and Company
Genzada Pharmaceuticals USA, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Stanford University
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)